Bristol submits hepatitis C drugs for FDA review

04/8/2014 | FDAnews

Bristol-Myers Squibb has filed new-drug applications with the FDA for approval to market its experimental drugs daclatasvir and asunaprevir as a treatment for hepatitis C genotype 1b. The combination regimen previously received breakthrough therapy status from the FDA.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA